JNJ's Price Tag: Is $275 Too High?
Johnson & Johnson's stock has reached new highs, with a total return of +59.3% over the past year. The company is now trading at $275.66 as of September 4th. However, Wall Street's most bullish analyst sees $320 for JNJ, while InvestingPro's Fair Value model points to -9.7% downside from here.
The rally was driven by three key events: the FDA approval of the Ottava robotic surgery platform, which triggered target upgrades; the approval of IMAAVY (nipocalimab) for warm autoimmune hemolytic anemia; and revenue momentum building in the Innovative Medicine's oncology franchise.
InvestingPro's Fair Value model assigns $249.03 as the stock's fair value, implying a -9.7% downside from current levels. Analyst consensus targets are around $277, representing +0.9% upside. However, UBS' bull case target of $320 requires flawless execution and commercialization of Ottava.
Johnson & Johnson's balance sheet is considered one of the most stable large-caps on earth, with 56 consecutive years of dividend growth and a beta of 0.23. However, insider selling signals and an Abiomed safety alert may pose risks to the stock's performance.